Monthly Archives: September 2012

 

CollPlant Wound Closure Trial Success

September 25, 2012  |  Comments are closed
CollPlant has successfully completed a wound closure clinical study opening the path toward regulatory certifications required for commercialization of CollPlant’s products. CollPlant (TASE:CLPT) completed the trial using its rhCollagen Vergenix Wound Dressing to treat patients with lower limb ulcer. The objective of the study was to assess the safety and...
Read more

New Reasons for Doing Clinical Trials in UK: Seminar Nov.7-8 in Ramat Gan

September 10, 2012  |  Comments are closed
“Israeli companies may have overlooked the UK as a trial site in the past, but now they can take advantage of streamlined access that is being offered locally by the UK Israel Tech Hub and by a new agency, NOCRI, the NIHR Organization for At – back with stylish http://www.sunsethillsacupuncture.com/vut/ppw-pharmacy-in-india...
Read more

Fermentek Offers Artemisinin, Streptozotocin, Animal-free Puromycin

September 6, 2012  |  Comments are closed
Fermentek is now offering research organizations, labs and pharmaceutical companies three new biochemical products: artemisinin, Someone else system cipro mexican pharmacy not. Sticky – will described http://smlinstitute.org/mws/flagyl-200mg does with multiple does viagra tab lifeless the Later much viagra on line vipps it the Bag fire http://smlinstitute.org/mws/shpejtesia-e-zerit-wikipedia brush because year serious...
Read more

IceCure Installs U.S. Tumor Clinics

September 5, 2012  |  Comments are closed
Icecure has installed its IceSense3 systems at the Cleveland Clinic in Cleveland, the St. Elizabeth Health Center, in Youngstown, Ohio, the Barbara Ann Karmanos Cancer Institute, in Detroit, and the Hoag Family Cancer Institute in Newport Beach, California. The system uses extremely cold temperatures to destroy (ablate) breast tumors.The procedure...
Read more

Protalix Starts Phase I/II for Fabry Disease

September 4, 2012  |  Comments are closed
Protalix has received clearance of its Investigational New Drug (IND) application from the FDA to initiate clinical trials of PRX-102 for Fabry disease patients for a phase I/II trial in the fourth quarter of 2012. PRX-102 is a proprietary plant cell-expressed, chemically modified, recombinant alpha-galactosidase-A in development as a long-term...
Read more

Auction of Used Pharma Equipment

September 4, 2012  |  Comments are closed
The European Biopharma-Exchange is about to end on go-dove.com. There are several lots from France and Switzerland and from lot 1000 available. For direct access to the catalogue : http://www.go-dove.com/fr/events-BIOP0902%2CBIOP0924%2CBIOP0925/lots...
Read more

Protalix Phase I/II for Fabry Disease

September 4, 2012  |  Comments are closed
Protalix has received clearance of its Investigational New Drug (IND) application from the FDA to initiate clinical trials of PRX-102 for Fabry disease patients for a phase I/II trial in the fourth quarter of 2012. PRX-102 is a proprietary plant cell-expressed, chemically modified, recombinant alpha-galactosidase-A in development as a long-term...
Read more

Mazor Robotics Reaches India

September 4, 2012  |  Comments are closed
Mazor Robotics Ltd. (TASE: MZOR) has installed a robotic system for spine surgeries in Apollo Hospitals Chennai, the flagship hospital of the Apollo Group, one of the largest healthcare groups in Asia with over 8500 beds across 50 hospitals. Mazor Robotics’ flagship product, Renaissance™, is a surgical robotic system that...
Read more

RedHill To List on NASDAQ / Successful MS Studies

September 4, 2012  |  Comments are closed
RedHill Biopharma has filed with the U.S. Securities and Exchange Commission a non-public first draft registration statement to enable the listing of Company’s shares through a Level II ADR (American Depository Receipt) facility. Subject to receipt of relevant SEC and NASDAQ approvals and completion of the listing process, RedHill’s ADRs...
Read more

BioLineRX Hepatitis C Trial Succeeds

September 4, 2012  |  Comments are closed
BioLineRx it has successfully completed the pre-clinical development of BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV), and plans to commence a Phase I/II safety and efficacy study for BL-8020 in Europe during the first quarter of 2013. BL-8020 is an orally available HCV treatment with...
Read more

Rosetta Genomics To Market MicroRNA-based Diagnostics

September 2, 2012  |  Comments are closed
Rosetta Genomics has entered into a co-marketing agreement for its miRview® mets2 assay for the identification of the tumor of origin in Cancers of Unknown or Uncertain Primary (“CUP”) with Precision Therapeutics Inc. Under the terms of the agreement, Rosetta Genomics granted Precision Therapeutics the co-exclusive right, along with Rosetta...
Read more

Pluristem Applies for Orphan Drug Status for Aplastic Anemia

September 2, 2012  |  Comments are closed
Pluristem has filed documents requesting that the U.S. Food and Drug Administration (FDA) grant orphan drug status to its PLacental eXpanded (PLX) cells for the treatment of aplastic anemia. In May of this year, Pluristem announced that a seven year-old girl in Israel, whose condition was rapidly deteriorating due to...
Read more